Gan & Lee Pharmaceuticals reports first-half 2026 net profit of 610 million yuan

Jiemian··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Gan & Lee Pharmaceuticals released its 2026 interim report, with total operating revenue of 2.223 billion yuan, net profit attributable to the parent company of 610 million yuan, and net operating cash inflow of 432 million yuan. The company's asset-liability ratio was 8.25%, gross margin was 74.13%, ROE was 5.21%, and diluted earnings per share was 1.03 yuan. The number of shareholders was 75,600, and the top ten shareholders held 49.82% of the total share capital.

Impact on assets 1

Others▲ · 1 stocks
© 2026 MarketIVNews